sny-20220630假象0001121404--12-316/30/20222022Q20.043478260869565200011214042022-01-012022-06-3000011214042022-06-30ISO4217：歐元00011214042021-12-3100011214042021-01-012021-06-3000011214042021-01-012021-12-31Xbrli：共享ISO4217：歐元Xbrli：共享0001121404IFRS-Full：IssuedCapitalMembers2019-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2019-12-310001121404IFRS-Full：財務份額成員2019-12-310001121404IFRS-Full：RetainedEarningsMembers2019-12-310001121404IFRS-FULL：基於共享的預留付款成員2019-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2019-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2019-12-310001121404IFRS-FULL：非控制性利益成員2019-12-3100011214042019-12-310001121404IFRS-Full：RetainedEarningsMembers2020-01-012020-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2020-01-012020-12-310001121404IFRS-FULL：非控制性利益成員2020-01-012020-12-3100011214042020-01-012020-12-310001121404IFRS-Full：財務份額成員2020-01-012020-12-310001121404IFRS-Full：IssuedCapitalMembers2020-01-012020-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2020-01-012020-12-310001121404IFRS-FULL：基於共享的預留付款成員2020-01-012020-12-310001121404IFRS-Full：IssuedCapitalMembers2020-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2020-12-310001121404IFRS-Full：財務份額成員2020-12-310001121404IFRS-Full：RetainedEarningsMembers2020-12-310001121404IFRS-FULL：基於共享的預留付款成員2020-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2020-12-310001121404IFRS-FULL：非控制性利益成員2020-12-3100011214042020-12-310001121404IFRS-Full：RetainedEarningsMembers2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2021-01-012021-06-300001121404IFRS-FULL：非控制性利益成員2021-01-012021-06-300001121404IFRS-Full：財務份額成員2021-01-012021-06-300001121404IFRS-FULL：AdditionalPidinCapitalMembers2021-01-012021-06-300001121404IFRS-Full：IssuedCapitalMembers2021-01-012021-06-300001121404IFRS-FULL：基於共享的預留付款成員2021-01-012021-06-300001121404IFRS-Full：IssuedCapitalMembers2021-06-300001121404IFRS-FULL：AdditionalPidinCapitalMembers2021-06-300001121404IFRS-Full：財務份額成員2021-06-300001121404IFRS-Full：RetainedEarningsMembers2021-06-300001121404IFRS-FULL：基於共享的預留付款成員2021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-06-300001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2021-06-300001121404IFRS-FULL：非控制性利益成員2021-06-3000011214042021-06-300001121404IFRS-Full：RetainedEarningsMembers2021-07-012021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2021-07-012021-12-310001121404IFRS-FULL：非控制性利益成員2021-07-012021-12-3100011214042021-07-012021-12-310001121404IFRS-Full：財務份額成員2021-07-012021-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2021-07-012021-12-310001121404IFRS-Full：IssuedCapitalMembers2021-07-012021-12-310001121404IFRS-FULL：基於共享的預留付款成員2021-07-012021-12-310001121404IFRS-Full：IssuedCapitalMembers2021-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2021-12-310001121404IFRS-Full：財務份額成員2021-12-310001121404IFRS-Full：RetainedEarningsMembers2021-12-310001121404IFRS-FULL：基於共享的預留付款成員2021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2021-12-310001121404IFRS-FULL：非控制性利益成員2021-12-310001121404IFRS-Full：RetainedEarningsMembers2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2022-01-012022-06-300001121404IFRS-FULL：非控制性利益成員2022-01-012022-06-300001121404SNY：Euroapi成員2022-01-012022-06-30Xbrli：純0001121404IFRS-Full：財務份額成員2022-01-012022-06-300001121404IFRS-Full：IssuedCapitalMembers2022-01-012022-06-300001121404IFRS-FULL：AdditionalPidinCapitalMembers2022-01-012022-06-300001121404IFRS-FULL：基於共享的預留付款成員2022-01-012022-06-300001121404IFRS-Full：IssuedCapitalMembers2022-06-300001121404IFRS-FULL：AdditionalPidinCapitalMembers2022-06-300001121404IFRS-Full：財務份額成員2022-06-300001121404IFRS-Full：RetainedEarningsMembers2022-06-300001121404IFRS-FULL：基於共享的預留付款成員2022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-06-300001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2022-06-300001121404IFRS-FULL：非控制性利益成員2022-06-300001121404SNY：Euroapi成員2022-05-102022-05-100001121404Sny:ConsumerHealthcareAndPharmaceuticalsMember2022-01-012022-06-30SNY：活動0001121404SNY：製藥公司成員2021-01-012021-06-300001121404SNY：製藥公司成員2021-01-012021-12-310001121404SNY：Consumer Healthcare成員2021-01-012021-12-310001121404國家/地區：AR2022-06-300001121404國家/地區：tr2022-06-3000011214042022-06-13SNY：試用版0001121404SNY：美國政府成員SNY：與GSK成員協作協議2022-01-012022-06-300001121404SNY：美國政府成員SNY：與GSK成員協作協議2021-01-012021-12-310001121404SNY：Amunix PharmPharmticalsIncMember2022-02-08ISO 4217：美元0001121404SNY：Amunix PharmPharmticalsIncMember2022-02-082022-06-300001121404SNY：Euroapi成員2022-03-172022-03-170001121404SNY：EPICBPIFranceMemberSNY：Euroapi成員2022-03-170001121404SNY：EPICBPIFranceMemberSNY：Euroapi成員2022-03-172022-03-170001121404SNY：Euroapi成員2022-05-102022-06-300001121404SNY：Euroapi成員2022-05-102022-05-100001121404SNY：Euroapi成員2022-05-032022-05-030001121404SNY：Euroapi成員2022-05-100001121404SNY：Euroapi成員2021-01-012021-12-310001121404SNY：EPICBPIFranceMemberSNY：Euroapi成員2022-06-172022-06-170001121404SNY：EPICBPIFranceMemberSNY：Euroapi成員2022-06-170001121404SNY：Euroapi成員2022-06-300001121404Ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember2022-05-100001121404SNY：監管合規性成本成員2022-05-100001121404SNY：Euroapi成員Sny:ManufactureAndSupplyCollaborationAgreementMember2021-10-012021-10-010001121404SNY：Euroapi成員Sny:ManufactureAndSupplyCollaborationAgreementMember2021-10-010001121404SNY：Euroapi成員Sny:ManufactureAndSupplyCollaborationAgreementMember2022-06-300001121404SNY：主要協作協議成員Sny:ImmunoOncologyCollaborationAgreementMemberSNY：更新換代製藥公司成員2022-07-012022-07-310001121404Sny:ImmunoOncologyCollaborationAgreementMemberSNY：更新換代製藥公司成員2022-06-012022-06-300001121404SNY：更新換代製藥公司成員2022-06-300001121404SNY：抗體協作協議成員SNY：更新換代製藥公司成員2022-01-012022-05-310001121404SNY：抗體協作協議成員SNY：更新換代製藥公司成員2022-06-012022-06-300001121404SNY：抗體協作協議成員SNY：更新換代製藥公司成員2022-01-012022-06-300001121404SNY：製藥公司成員2022-01-012022-06-300001121404SNY：製藥公司成員2021-01-012021-12-310001121404SNY：製藥公司成員SNY：IndustrialFacilities成員2022-01-012022-06-300001121404SNY：製藥公司成員SNY：IndustrialFacilities成員2021-01-012021-12-310001121404SNY：製藥公司成員SNY：研究站點成員2022-01-012022-06-300001121404SNY：製藥公司成員SNY：研究站點成員2021-01-012021-12-310001121404SNY：製藥公司成員SNY：其他成員2022-01-012022-06-300001121404SNY：製藥公司成員SNY：其他成員2021-01-012021-12-310001121404SNY：疫苗成員2022-01-012022-06-300001121404SNY：疫苗成員2021-01-012021-12-310001121404SNY：Consumer Healthcare成員2022-01-012022-06-300001121404SNY：Consumer Healthcare成員2021-01-012021-12-310001121404SNY：獲取的RAND成員IFRS-Full：Gross CarryingAmount Member2021-12-310001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIFRS-Full：Gross CarryingAmount Member2021-12-310001121404IFRS-FULL：計算機軟件成員IFRS-Full：Gross CarryingAmount Member2021-12-310001121404IFRS-Full：Gross CarryingAmount Member2021-12-310001121404SNY：獲取的RAND成員IFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404IFRS-FULL：計算機軟件成員IFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404IFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404SNY：獲取的RAND成員IFRS-Full：Gross CarryingAmount Member2022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIFRS-Full：Gross CarryingAmount Member2022-06-300001121404IFRS-FULL：計算機軟件成員IFRS-Full：Gross CarryingAmount Member2022-06-300001121404IFRS-Full：Gross CarryingAmount Member2022-06-300001121404SNY：獲取的RAND成員Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404IFRS-FULL：計算機軟件成員Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404SNY：獲取的RAND成員Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404IFRS-FULL：計算機軟件成員Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404SNY：獲取的RAND成員Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404IFRS-FULL：計算機軟件成員Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404SNY：獲取的RAND成員2021-12-310001121404Sny:MarketedProductsTrademarksAndOtherRightsMember2021-12-310001121404IFRS-FULL：計算機軟件成員2021-12-310001121404SNY：獲取的RAND成員2022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMember2022-06-300001121404IFRS-FULL：計算機軟件成員2022-06-300001121404SNY：Amunix PharmPharmticalsIncMemberSny:MarketedProductsTrademarksAndOtherRightsMemberIFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404SNY：LibtayoMembersIFRS-FULL：非當前資產HeldForSaleMemberIFRS-Full：Gross CarryingAmount Member2022-06-300001121404SNY：LibtayoMembersIFRS-FULL：非當前資產HeldForSaleMemberIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404SNY：EnjaymoMembers2022-01-012022-06-300001121404SNY：EnjaymoMembersIFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404SNY：EnjaymoMembersIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404SNY：技術平臺成員2022-01-012022-06-300001121404Sny:OtherIntangibleAssetsExcludingSoftwareMember2022-01-012022-06-300001121404SNY：市場化產品成員2022-06-300001121404SNY：市場化產品成員2021-12-310001121404SNY：市場化產品成員2022-01-012022-06-300001121404SNY：技術平臺成員2022-06-300001121404SNY：技術平臺成員2021-12-310001121404SNY：Euroapi成員2022-01-012022-06-300001121404SNY：Euroapi成員2021-12-310001121404SNY：InfraservGmbhAndCoHochstKGMember2022-01-012022-06-300001121404SNY：InfraservGmbhAndCoHochstKGMember2022-06-300001121404SNY：InfraservGmbhAndCoHochstKGMember2021-12-310001121404SNY：MSPVaccineCompany成員2022-01-012022-06-300001121404SNY：MSPVaccineCompany成員2022-06-300001121404SNY：MSPVaccineCompany成員2021-12-310001121404Ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2022-01-012022-06-300001121404Ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2022-06-300001121404Ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2021-12-310001121404SNY：MCMVaccineBVMembersSNY：MSPVaccineCompany成員2022-01-012022-06-300001121404SNY：AssociatesAndJointVenturesMembers2022-01-012022-06-300001121404SNY：AssociatesAndJointVenturesMembers2021-01-012021-06-300001121404SNY：AssociatesAndJointVenturesMembers2021-01-012021-12-310001121404SNY：AssociatesAndJointVenturesMembers2022-06-300001121404SNY：AssociatesAndJointVenturesMembers2021-06-300001121404SNY：AssociatesAndJointVenturesMembers2021-12-310001121404IFRS-Full：TradingEquitySecuritiesMembers2022-06-300001121404IFRS-Full：TradingEquitySecuritiesMembers2021-12-310001121404IFRS-Full：債務證券成員2022-06-300001121404IFRS-Full：債務證券成員2021-12-310001121404SNY：ExScience成員2022-01-072022-01-070001121404SNY：IGM BiosciencesIncMember2022-03-292022-03-290001121404IFRS-FULL：AllowanceForCreditLosesMember2022-06-300001121404IFRS-FULL：AllowanceForCreditLosesMember2021-12-310001121404IFRS-Full：非晚於一個月成員2022-06-300001121404Ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2022-06-300001121404Ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2022-06-300001121404Ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2022-06-300001121404IFRS-Full：晚於一年成員2022-06-300001121404IFRS-Full：非晚於一個月成員2021-12-310001121404Ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2021-12-310001121404Ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2021-12-310001121404Ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2021-12-310001121404IFRS-Full：晚於一年成員2021-12-310001121404IFRS-Full：IssuedCapitalMembers紐約：SanofiMembers2022-01-012022-06-300001121404SNY：共享回購2021計劃成員2021-04-302021-04-300001121404SNY：共享回購2021計劃成員2021-01-012021-06-300001121404SNY：共享回購2021計劃成員2021-06-300001121404SNY：共享回購2022計劃成員2022-05-032022-05-030001121404SNY：受限共享計劃2022成員2022-01-012022-06-300001121404SNY：受限共享計劃2022成員SNY：無市場條件成員2022-01-012022-06-300001121404SNY：具有市場條件成員SNY：受限共享計劃2022成員2022-01-012022-06-300001121404SNY：具有市場條件成員SNY：受限共享計劃2022成員SNY：排除首席執行官ExecutiveOfficerMember2022-01-012022-06-300001121404SNY：具有市場條件成員Sny:RestrictedSharePlan2022AdditionalSharesMemberSNY：排除首席執行官ExecutiveOfficerMember2022-01-012022-06-300001121404SNY：具有市場條件成員SNY：受限共享計劃2022成員SRT：首席執行官執行官員成員2022-01-012022-06-300001121404SNY：受限共享成員2022-01-012022-06-300001121404SNY：受限共享成員2021-01-012021-06-300001121404SNY：受限共享成員2022-06-300001121404SNY：受限共享成員2021-06-300001121404SNY：受限共享計劃2022成員2022-06-300001121404SNY：受限共享計劃2022成員2021-06-300001121404SNY：受限共享計劃2021成員2022-06-300001121404SNY：受限共享計劃2021成員2021-06-300001121404SNY：受限共享計劃2020成員2022-06-300001121404SNY：受限共享計劃2020成員2021-06-300001121404SNY：受限共享計劃2019年成員2022-06-300001121404SNY：受限共享計劃2019年成員2021-06-300001121404SNY：受限共享計劃2018年成員2022-06-300001121404SNY：受限共享計劃2018年成員2021-06-300001121404SNY：EmployeeShareOwnership PlanMember2022-02-030001121404SNY：EmployeeShareOwnership PlanMember2022-06-290001121404SNY：EmployeeShareOwnership PlanMember2022-01-012022-06-300001121404SNY：EmployeeShareOwnership PlanMember2021-02-040001121404SNY：EmployeeShareOwnership PlanMember2021-06-250001121404SNY：EmployeeShareOwnership PlanMember2021-01-012021-06-300001121404IFRS-FULL：底部範圍成員SNY：股票選項計劃成員SNY：ExercisePriceRange兩成員2022-06-300001121404SNY：股票選項計劃成員IFRS-Full：TopOfRangeMemberSNY：ExercisePriceRange兩成員2022-06-300001121404SNY：股票選項計劃成員SNY：ExercisePriceRange兩成員2022-06-300001121404SNY：股票選項計劃成員SNY：ExercisePriceRange兩成員2022-01-012022-06-300001121404IFRS-FULL：底部範圍成員SNY：股票選項計劃成員SNY：練習PriceRange3成員2022-06-300001121404SNY：股票選項計劃成員IFRS-Full：TopOfRangeMemberSNY：練習PriceRange3成員2022-06-300001121404SNY：股票選項計劃成員SNY：練習PriceRange3成員2022-06-300001121404SNY：股票選項計劃成員SNY：練習PriceRange3成員2022-01-012022-06-300001121404SNY：ExercisePriceRange4成員IFRS-FULL：底部範圍成員SNY：股票選項計劃成員2022-06-300001121404SNY：ExercisePriceRange4成員SNY：股票選項計劃成員IFRS-Full：TopOfRangeMember2022-06-300001121404SNY：ExercisePriceRange4成員SNY：股票選項計劃成員2022-06-300001121404SNY：ExercisePriceRange4成員SNY：股票選項計劃成員2022-01-012022-06-300001121404SNY：股票選項計劃成員2022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:EquityInstrumentsIncludedInFinancialAssetsMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:EquityInstrumentsIncludedInFinancialAssetsMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:EquityInstrumentsIncludedInFinancialAssetsMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：債務工具成員2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：債務工具成員2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：債務工具成員2021-01-012021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：債務工具成員2022-01-012022-06-300001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：債務工具成員2021-01-012021-12-310001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404SNY：攤銷成本淨額成員2022-06-300001121404SNY：調整至負債測量屬性公允價值成員2022-06-300001121404SNY：ValueOnRedemptionMember2022-06-300001121404SNY：ValueOnRedemptionMember2021-12-310001121404SNY：非當前責任成員SNY：ValueOnRedemptionMember2022-06-300001121404SNY：ValueOnRedemptionMemberSNY：當前責任成員2022-06-300001121404SNY：非當前責任成員SNY：ValueOnRedemptionMember2021-12-310001121404SNY：ValueOnRedemptionMemberSNY：當前責任成員2021-12-310001121404SNY：ValueOnRedemptionMemberSNY：非當前資產成員2022-06-300001121404SNY：ValueOnRedemptionMemberSNY：當前資產成員2022-06-300001121404SNY：ValueOnRedemptionMemberSNY：非當前資產成員2021-12-310001121404SNY：ValueOnRedemptionMemberSNY：當前資產成員2021-12-310001121404Sny:OneBillionFiveHundredMillionBondsIssuedInApril2022Member2022-04-30SNY：部分0001121404Sny:EightHundredAndFiftyMillionOfFixedRateBondsMaturingAprilTwoThousandTwentyFiveMember2022-04-300001121404Sny:SixHundredAndFiftyMillionOfFixedRateBondsMaturingAprilTwoThousandTwentyNineMember2022-04-30SNY：患者SNY：國家SNY：債券0001121404SNY：2022年1月到期的10億債券2014-09-300001121404Sny:EightHundredFiftyMillionBondsMaturingFebruary2022Member2019-03-310001121404Sny:EightHundredFiftyMillionBondsMaturingJune2022Member2016-09-300001121404SNY：SyndicatedCreditFacilityOneMember2022-06-300001121404SNY：SyndicatedCreditFacilityTwoMember2022-06-300001121404SNY：SyndicatedCreditFacilityTwoMember2022-01-012022-06-300001121404SNY：法國商業紙業計劃成員2022-06-300001121404SNY：美國商業紙張計劃成員2022-06-300001121404SNY：美國商業紙張計劃成員2022-01-012022-06-300001121404SNY：AtMarketValueMember2022-06-300001121404SNY：AtMarketValueMember2021-12-310001121404SNY：ValueOnRedemptionMember2022-01-012022-06-300001121404SNY：ValueOnRedemptionMember2021-01-012021-12-310001121404SNY：ForwardCurrencySalesMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesMember2022-06-300001121404SNY：ForwardCurrencySalesMemberIFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesMemberIFRS-Full：現金流量對衝成員2022-06-300001121404SNY：ForwardCurrencySalesMemberIFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404SNY：ForwardCurrencySalesMemberSNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesMemberSNY：NotEligibleForHedgeAccount成員2022-06-300001121404SNY：ForwardCurrencySalesInUSDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesInUSDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404SNY：ForwardCurrencySalesInUSDollarMemberSNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesInUSDollarMemberSNY：NotEligibleForHedgeAccount成員2022-06-300001121404SNY：AtNotionalAmount成員Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404SNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：NotEligibleForHedgeAccount成員Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404Sny:ForwardCurrencySalesInSingaporeDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404IFRS-Full：現金流量對衝成員Sny:ForwardCurrencySalesInSingaporeDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404Sny:ForwardCurrencySalesInSingaporeDollarMemberSNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencySalesInSingaporeDollarMemberSNY：NotEligibleForHedgeAccount成員2022-06-300001121404SNY：ForwardCurrencySalesin Japan YenMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesin Japan YenMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesin Japan YenMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesin Japan YenMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesin Japan YenMemberSNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404SNY：ForwardCurrencySalesin Japan YenMemberSNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesin Japan YenMemberSNY：NotEligibleForHedgeAccount成員2022-06-300001121404SNY：ForwardCurrencySalesin Korea WonMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesin Korea WonMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesin Korea WonMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesin Korea WonMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesin Korea WonMemberSNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404SNY：ForwardCurrencySalesin Korea WonMemberSNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesin Korea WonMemberSNY：NotEligibleForHedgeAccount成員2022-06-300001121404SNY：遠期現貨採購成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：遠期現貨採購成員2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：遠期現貨採購成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員SNY：遠期現貨採購成員2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSNY：遠期現貨採購成員2022-06-300001121404SNY：遠期現貨採購成員SNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：遠期現貨採購成員SNY：NotEligibleForHedgeAccount成員2022-06-300001121404SNY：遠期現貨購買量美元成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：遠期現貨購買量美元成員2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：遠期現貨購買量美元成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員SNY：遠期現貨購買量美元成員2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSNY：遠期現貨購買量美元成員2022-06-300001121404SNY：遠期現貨購買量美元成員SNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：遠期現貨購買量美元成員SNY：NotEligibleForHedgeAccount成員2022-06-300001121404Sny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404IFRS-Full：現金流量對衝成員Sny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404Sny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：NotEligibleForHedgeAccount成員2022-06-300001121404SNY：結轉貨幣購買在韓國韓元成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：結轉貨幣購買在韓國韓元成員2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：結轉貨幣購買在韓國韓元成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員SNY：結轉貨幣購買在韓國韓元成員2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSNY：結轉貨幣購買在韓國韓元成員2022-06-300001121404SNY：結轉貨幣購買在韓國韓元成員SNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：結轉貨幣購買在韓國韓元成員SNY：NotEligibleForHedgeAccount成員2022-06-300001121404SNY：AtNotionalAmount成員Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404SNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：NotEligibleForHedgeAccount成員Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404SNY：AtNotionalAmount成員Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404SNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：NotEligibleForHedgeAccount成員Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMember2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404SNY：NotEligibleForHedgeAccount成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：NotEligibleForHedgeAccount成員2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404IFRS-Full：不晚於一年成員SNY：ForwardCurrencySalesInUSDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：不晚於一年成員SNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404IFRS-Full：不晚於一年成員Sny:ForwardCurrencySalesInSingaporeDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：不晚於一年成員Sny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404IFRS-Full：不晚於一年成員SNY：AtNotionalAmount成員SNY：ForwardCurrencySalesInPoundSterlingMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：不晚於一年成員SNY：ForwardCurrencySalesInPoundSterlingMember2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：遠期現貨購買量美元成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIfrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：遠期現貨購買量美元成員2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIfrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404IFRS-Full：不晚於一年成員SNY：AtNotionalAmount成員Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：不晚於一年成員Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404SNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404Sny:ForwardCurrencySalesInSingaporeDollarMember2022-06-30ISO 4217：SGD0001121404Sny:ForwardCurrencyPurchasesInUSDollarUSBondMember2022-06-300001121404Sny:ForwardCurrencyPurchasesInUSDollarUSBondMember2022-01-012022-06-300001121404Sny:ForwardCurrencyPurchasesInUSDollarIntragroupAccountMember2022-06-300001121404Sny:ForwardCurrencyPurchasesInUSDollarIntragroupAccountMember2022-01-012022-06-300001121404Sny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404Sny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-01-012022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：不晚於一年成員SNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404Ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404SNY：AtNotionalAmount成員Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMemberSny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404SNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：FairValueHedgesMemberSny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMember2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：不晚於一年成員SNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIfrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberSNY：AtNotionalAmount成員Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIfrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：AtFairValueMember2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：FairValueHedgesMember2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：現金流量對衝成員2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：不晚於一年成員SNY：AtNotionalAmount成員2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberSNY：AtNotionalAmount成員Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIfrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：FairValueHedgesMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：現金流量對衝成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：不晚於一年成員SNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIfrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberSNY：AtNotionalAmount成員Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIfrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：AtFairValueMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：AtFairValueMemberIFRS-Full：FairValueHedgesMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404IFRS-Full：不晚於一年成員Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成員2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成員Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedEsterReceive069MemberIFRS-Full：FairValueHedgesMember2022-06-300001121404IFRS-Full：現金流量對衝成員Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404IFRS-Full：現金流量對衝成員Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：不晚於一年成員SNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404Ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404SNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092MemberIfrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404SNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：FairValueHedgesMemberSny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：AtNotionalAmount成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404IFRS-Full：不晚於一年成員Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成員2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成員Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成員2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberIFRS-Full：FairValueHedgesMember2022-06-300001121404IFRS-Full：現金流量對衝成員Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：現金流量對衝成員Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404IFRS-Full：現金流量對衝成員SNY：ValueOfHedgeRecognizedInEquityMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404IFRS-Full：不晚於一年成員SNY：AtNotionalAmount成員2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404Ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404SNY：AtNotionalAmount成員Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成員2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：FairValueHedgesMember2022-06-300001121404Sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2021-12-310001121404Sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2021-12-310001121404Sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2021-12-310001121404Sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2021-12-310001121404SNY：其他責任1成員2021-12-310001121404Sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-01-012022-06-300001121404Sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2022-01-012022-06-300001121404Sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2022-01-012022-06-300001121404Sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2022-01-012022-06-300001121404SNY：其他責任1成員2022-01-012022-06-300001121404Sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-06-300001121404Sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2022-06-300001121404Sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2022-06-300001121404Sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2022-06-300001121404SNY：其他責任1成員2022-06-300001121404IFRS-Full：TopOfRangeMemberSny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-01-012022-06-300001121404Sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2021-12-310001121404SNY：其他長期福利撥備成員2021-12-310001121404SNY：非當前重構配置成員2021-12-310001121404IFRS-Full：雜項其他撥備成員2021-12-310001121404Sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2022-01-012022-06-300001121404SNY：其他長期福利撥備成員2022-01-012022-06-300001121404SNY：非當前重構配置成員2022-01-012022-06-300001121404IFRS-Full：雜項其他撥備成員2022-01-012022-06-300001121404Sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2022-06-300001121404SNY：其他長期福利撥備成員2022-06-300001121404SNY：非當前重構配置成員2022-06-300001121404IFRS-Full：雜項其他撥備成員2022-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMemberIFRS-FULL：計劃資產成員2022-01-012022-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMemberIFRS-FULL：計劃資產成員2021-01-012021-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMemberIFRS-FULL：計劃資產成員2021-01-012021-12-310001121404Sny:PensionsAndOtherPostEmploymentBenefitsMember2022-01-012022-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMember2021-01-012021-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMember2021-01-012021-12-310001121404Ifrs-full:ActuarialAssumptionOfDiscountRatesMemberSRT：最小成員數2022-06-300001121404Ifrs-full:ActuarialAssumptionOfDiscountRatesMemberSRT：最大成員數2022-06-300001121404國家：GBIfrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember2022-06-300001121404Ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMemberSNY：歐洲經濟區成員2022-06-300001121404Ifrs-full:ActuarialAssumptionOfDiscountRatesMemberSRT：最大成員數2021-06-300001121404Ifrs-full:ActuarialAssumptionOfDiscountRatesMemberSRT：最小成員數2021-06-300001121404國家：GBIfrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember2021-06-300001121404Ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMemberSNY：歐洲經濟區成員2021-06-300001121404SNY：ExScience成員SRT：最大成員數2022-01-07SNY：分子0001121404SNY：ABLBioMembers2022-01-112022-01-110001121404SNY：ABLBioMembersSRT：最大成員數2022-01-110001121404SNY：AdageneIncMember2022-03-022022-03-020001121404SNY：AdageneIncMemberSRT：最大成員數2022-03-020001121404SNY：抗體協作協議成員SNY：Blackstone生命科學成員2022-03-152022-03-150001121404SNY：IGM BiosciencesIncMemberSRT：最大成員數2022-03-29SNY：目標0001121404SNY：生產責任成員SNY：ActionForWhichWeAreDefendantMemberSNY：ZantacProductLitigationin the US成員2022-06-300001121404SNY：生產責任成員SNY：ActionForWhichWeAreDefendantMemberSNY：DepakineProductLitigationIn FranceMember2022-05-120001121404SNY：生產責任成員SNY：ActionForWhichWeAreDefendantMemberSNY：DepakineProductLitigationIn FranceMember2022-05-122022-05-120001121404SNY：西班牙DepakineProductLitigationin成員SNY：生產責任成員SNY：ActionForWhichWeAreDefendantMember2022-03-17SNY：索賠人0001121404SNY：西班牙DepakineProductLitigationin成員SNY：生產責任成員SNY：ActionForWhichWeAreDefendantMember2022-03-172022-03-170001121404SNY：其他運營收入支出成員IFRS-Full：OtherRelatedPartiesMember2022-01-012022-06-300001121404SNY：其他運營收入支出成員IFRS-Full：OtherRelatedPartiesMember2021-01-012021-06-300001121404SNY：其他運營收入支出成員SNY：更新成員2022-01-012022-06-300001121404SNY：其他運營收入支出成員SNY：更新成員2021-01-012021-06-300001121404SNY：第一三代成員SNY：其他運營收入支出成員2021-01-012021-06-300001121404SNY：商業化相關費用成員SNY：更新成員IFRS-Full：OtherRelatedPartiesMember2022-01-012022-06-300001121404SNY：商業化相關費用成員SNY：更新成員IFRS-Full：OtherRelatedPartiesMember2021-01-012021-06-300001121404Sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMemberSNY：抗體聯盟成員2022-01-012022-06-300001121404Sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMemberSNY：抗體聯盟成員2021-01-012021-06-300001121404Sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMemberSNY：抗體聯盟成員2021-01-012021-12-310001121404SNY：抗體聯盟成員Sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2022-01-012022-06-300001121404SNY：抗體聯盟成員Sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2021-01-012021-06-300001121404SNY：抗體聯盟成員Sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2021-01-012021-12-310001121404SNY：抗體聯盟成員SNY：商業化相關費用成員2022-01-012022-06-300001121404SNY：抗體聯盟成員SNY：商業化相關費用成員2021-01-012021-06-300001121404SNY：抗體聯盟成員SNY：商業化相關費用成員2021-01-012021-12-310001121404SNY：抗體聯盟成員2022-01-012022-06-300001121404SNY：抗體聯盟成員2021-01-012021-06-300001121404SNY：抗體聯盟成員2021-01-012021-12-310001121404SNY：免疫腫瘤學聯盟成員2022-01-012022-06-300001121404SNY：免疫腫瘤學聯盟成員2021-01-012021-06-300001121404SNY：免疫腫瘤學聯盟成員2021-01-012021-12-310001121404SNY：其他交易對手成員2022-01-012022-06-300001121404SNY：其他交易對手成員2021-01-012021-06-300001121404SNY：其他交易對手成員2021-01-012021-12-310001121404SNY：其他運營收入支出成員SNY：更新成員2021-01-012021-12-3100011214042021-07-012022-06-300001121404SNY：利率和貨幣衍生品成員2022-01-012022-06-300001121404SNY：利率和貨幣衍生品成員2021-01-012021-06-300001121404SNY：利率和貨幣衍生品成員2021-01-012021-12-31SNY：線段0001121404SNY：製藥部門成員SRT：歐洲成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員2022-01-012022-06-300001121404SNY：製藥部門成員2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員2021-01-012021-06-300001121404SNY：製藥部門成員2021-01-012021-06-300001121404SNY：General MedicineMemberSNY：製藥部門成員SRT：歐洲成員2022-01-012022-06-300001121404國家：美國SNY：General MedicineMemberSNY：製藥部門成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：General MedicineMemberSNY：製藥部門成員2022-01-012022-06-300001121404SNY：General MedicineMemberSNY：製藥部門成員2022-01-012022-06-300001121404SNY：General MedicineMemberSNY：製藥部門成員SRT：歐洲成員2021-01-012021-06-300001121404國家：美國SNY：General MedicineMemberSNY：製藥部門成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：General MedicineMemberSNY：製藥部門成員2021-01-012021-06-300001121404SNY：General MedicineMemberSNY：製藥部門成員2021-01-012021-06-300001121404SNY：製藥部門成員SNY：Lantus成員SRT：歐洲成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：Lantus成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：Lantus成員2022-01-012022-06-300001121404SNY：製藥部門成員SNY：Lantus成員2022-01-012022-06-300001121404SNY：製藥部門成員SNY：Lantus成員SRT：歐洲成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：Lantus成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：Lantus成員2021-01-012021-06-300001121404SNY：製藥部門成員SNY：Lantus成員2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：ToujeoMember2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：ToujeoMember2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：ToujeoMember2022-01-012022-06-300001121404SNY：製藥部門成員SNY：ToujeoMember2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：ToujeoMember2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：ToujeoMember2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：ToujeoMember2021-01-012021-06-300001121404SNY：製藥部門成員SNY：ToujeoMember2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：Praluent成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：Praluent成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：Praluent成員2022-01-012022-06-300001121404SNY：製藥部門成員SNY：Praluent成員2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：Praluent成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：Praluent成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：Praluent成員2021-01-012021-06-300001121404SNY：製藥部門成員SNY：Praluent成員2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：多個成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：多個成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：多個成員2022-01-012022-06-300001121404SNY：製藥部門成員SNY：多個成員2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：多個成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：多個成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：多個成員2021-01-012021-06-300001121404SNY：製藥部門成員SNY：多個成員2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：LovenoxMember2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：LovenoxMember2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：LovenoxMember2022-01-012022-06-300001121404SNY：製藥部門成員SNY：LovenoxMember2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：LovenoxMember2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：LovenoxMember2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：LovenoxMember2021-01-012021-06-300001121404SNY：製藥部門成員SNY：LovenoxMember2021-01-012021-06-300001121404SNY：PlavixMemberSNY：製藥部門成員SRT：歐洲成員2022-01-012022-06-300001121404國家：美國SNY：PlavixMemberSNY：製藥部門成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：PlavixMemberSNY：製藥部門成員2022-01-012022-06-300001121404SNY：PlavixMemberSNY：製藥部門成員2022-01-012022-06-300001121404SNY：PlavixMemberSNY：製藥部門成員SRT：歐洲成員2021-01-012021-06-300001121404國家：美國SNY：PlavixMemberSNY：製藥部門成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：PlavixMemberSNY：製藥部門成員2021-01-012021-06-300001121404SNY：PlavixMemberSNY：製藥部門成員2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：胸腺球蛋白成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：胸腺球蛋白成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：胸腺球蛋白成員2022-01-012022-06-300001121404SNY：製藥部門成員SNY：胸腺球蛋白成員2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：胸腺球蛋白成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：胸腺球蛋白成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：胸腺球蛋白成員2021-01-012021-06-300001121404SNY：製藥部門成員SNY：胸腺球蛋白成員2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：行業銷售成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：行業銷售成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：行業銷售成員2022-01-012022-06-300001121404SNY：製藥部門成員SNY：行業銷售成員2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：行業銷售成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：行業銷售成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：行業銷售成員2021-01-012021-06-300001121404SNY：製藥部門成員SNY：行業銷售成員2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：Special CareMember2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：Special CareMember2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：Special CareMember2022-01-012022-06-300001121404SNY：製藥部門成員SNY：Special CareMember2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：Special CareMember2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：Special CareMember2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：Special CareMember2021-01-012021-06-300001121404SNY：製藥部門成員SNY：Special CareMember2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員紐約：8月bagio成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員紐約：8月bagio成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員紐約：8月bagio成員2022-01-012022-06-300001121404SNY：製藥部門成員紐約：8月bagio成員2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員紐約：8月bagio成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員紐約：8月bagio成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員紐約：8月bagio成員2021-01-012021-06-300001121404SNY：製藥部門成員紐約：8月bagio成員2021-01-012021-06-300001121404SNY：Cerezyme成員SNY：製藥部門成員SRT：歐洲成員2022-01-012022-06-300001121404國家：美國SNY：Cerezyme成員SNY：製藥部門成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：Cerezyme成員SNY：製藥部門成員2022-01-012022-06-300001121404SNY：Cerezyme成員SNY：製藥部門成員2022-01-012022-06-300001121404SNY：Cerezyme成員SNY：製藥部門成員SRT：歐洲成員2021-01-012021-06-300001121404國家：美國SNY：Cerezyme成員SNY：製藥部門成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：Cerezyme成員SNY：製藥部門成員2021-01-012021-06-300001121404SNY：Cerezyme成員SNY：製藥部門成員2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：MyozymeOrLumizymeMember2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：MyozymeOrLumizymeMember2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：MyozymeOrLumizymeMember2022-01-012022-06-300001121404SNY：製藥部門成員SNY：MyozymeOrLumizymeMember2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：MyozymeOrLumizymeMember2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：MyozymeOrLumizymeMember2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：MyozymeOrLumizymeMember2021-01-012021-06-300001121404SNY：製藥部門成員SNY：MyozymeOrLumizymeMember2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：Fradzyme成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：Fradzyme成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：Fradzyme成員2022-01-012022-06-300001121404SNY：製藥部門成員SNY：Fradzyme成員2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：Fradzyme成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：Fradzyme成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：Fradzyme成員2021-01-012021-06-300001121404SNY：製藥部門成員SNY：Fradzyme成員2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：ELoctateMember2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員SNY：ELoctateMember2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：ELoctateMember2022-01-012022-06-300001121404SNY：製藥部門成員SNY：ELoctateMember2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員SNY：ELoctateMember2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員SNY：ELoctateMember2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員SNY：ELoctateMember2021-01-012021-06-300001121404SNY：製藥部門成員SNY：ELoctateMember2021-01-012021-06-300001121404SNY：製藥部門成員SRT：歐洲成員紐約：傑夫塔納成員2022-01-012022-06-300001121404國家：美國SNY：製藥部門成員紐約：傑夫塔納成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員紐約：傑夫塔納成員2022-01-012022-06-300001121404SNY：製藥部門成員紐約：傑夫塔納成員2022-01-012022-06-300001121404SNY：製藥部門成員SRT：歐洲成員紐約：傑夫塔納成員2021-01-012021-06-300001121404國家：美國SNY：製藥部門成員紐約：傑夫塔納成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：製藥部門成員紐約：傑夫塔納成員2021-01-012021-06-300001121404SNY：製藥部門成員紐約：傑夫塔納成員2021-01-012021-06-300001121404紐約：DupixentMemberSNY：製藥部門成員SRT：歐洲成員2022-01-012022-06-300001121404國家：美國紐約：DupixentMemberSNY：製藥部門成員2022-01-012022-06-300001121404SNY：其他國家/地區成員紐約：DupixentMemberSNY：製藥部門成員2022-01-012022-06-300001121404紐約：DupixentMemberSNY：製藥部門成員2022-01-012022-06-300001121404紐約：DupixentMemberSNY：製藥部門成員SRT：歐洲成員2021-01-012021-06-300001121404國家：美國紐約：DupixentMemberSNY：製藥部門成員2021-01-012021-06-300001121404SNY：其他國家/地區成員紐約：DupixentMemberSNY：製藥部門成員2021-01-012021-06-300001121404紐約：DupixentMemberSNY：製藥部門成員2021-01-012021-06-300001121404SNY：疫苗部門成員SRT：歐洲成員2022-01-012022-06-300001121404國家：美國SNY：疫苗部門成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：疫苗部門成員2022-01-012022-06-300001121404SNY：疫苗部門成員2022-01-012022-06-300001121404SNY：疫苗部門成員SRT：歐洲成員2021-01-012021-06-300001121404國家：美國SNY：疫苗部門成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：疫苗部門成員2021-01-012021-06-300001121404SNY：疫苗部門成員2021-01-012021-06-300001121404SNY：疫苗部門成員SRT：歐洲成員SNY：脊髓灰質炎疫苗成員2022-01-012022-06-300001121404國家：美國SNY：疫苗部門成員SNY：脊髓灰質炎疫苗成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：疫苗部門成員SNY：脊髓灰質炎疫苗成員2022-01-012022-06-300001121404SNY：疫苗部門成員SNY：脊髓灰質炎疫苗成員2022-01-012022-06-300001121404SNY：疫苗部門成員SRT：歐洲成員SNY：脊髓灰質炎疫苗成員2021-01-012021-06-300001121404國家：美國SNY：疫苗部門成員SNY：脊髓灰質炎疫苗成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：疫苗部門成員SNY：脊髓灰質炎疫苗成員2021-01-012021-06-300001121404SNY：疫苗部門成員SNY：脊髓灰質炎疫苗成員2021-01-012021-06-300001121404SNY：疫苗部門成員SRT：歐洲成員SNY：流感疫苗成員2022-01-012022-06-300001121404國家：美國SNY：疫苗部門成員SNY：流感疫苗成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：疫苗部門成員SNY：流感疫苗成員2022-01-012022-06-300001121404SNY：疫苗部門成員SNY：流感疫苗成員2022-01-012022-06-300001121404SNY：疫苗部門成員SRT：歐洲成員SNY：流感疫苗成員2021-01-012021-06-300001121404國家：美國SNY：疫苗部門成員SNY：流感疫苗成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：疫苗部門成員SNY：流感疫苗成員2021-01-012021-06-300001121404SNY：疫苗部門成員SNY：流感疫苗成員2021-01-012021-06-300001121404SRT：歐洲成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404國家：美國SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SRT：歐洲成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404國家：美國SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：所有成員SRT：歐洲成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404國家：美國SNY：所有成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：所有成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：所有成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：所有成員SRT：歐洲成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404國家：美國SNY：所有成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：所有成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：所有成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SRT：歐洲成員SNY：PainCareMemberSNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404國家：美國SNY：PainCareMemberSNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：PainCareMemberSNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：PainCareMemberSNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SRT：歐洲成員SNY：PainCareMemberSNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404國家：美國SNY：PainCareMemberSNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：PainCareMemberSNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：PainCareMemberSNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：消化健康成員SRT：歐洲成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404國家：美國SNY：消化健康成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：其他國家/地區成員SNY：消化健康成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：消化健康成員SNY：Consumer Healthcare細分市場成員2022-01-012022-06-300001121404SNY：消化健康成員SRT：歐洲成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404國家：美國SNY：消化健康成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：其他國家/地區成員SNY：消化健康成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SNY：消化健康成員SNY：Consumer Healthcare細分市場成員2021-01-012021-06-300001121404SRT：歐洲成員2022-01-012022-06-300001121404國家：美國2022-01-012022-06-300001121404SNY：其他國家/地區成員2022-01-012022-06-300001121404SRT：歐洲成員2021-01-012021-06-300001121404國家：美國2021-01-012021-06-300001121404SNY：其他國家/地區成員2021-01-012021-06-300001121404IFRS-Full：所有其他部門成員2022-01-012022-06-300001121404IFRS-Full：可報告部門成員2022-01-012022-06-300001121404IFRS-Full：所有其他部門成員2021-01-012021-06-300001121404IFRS-Full：可報告部門成員2021-01-012021-06-300001121404SNY：製藥部門成員2021-01-012021-12-310001121404SNY：疫苗部門成員2021-01-012021-12-310001121404SNY：Consumer Healthcare細分市場成員2021-01-012021-12-310001121404IFRS-Full：所有其他部門成員2021-01-012021-12-310001121404IFRS-Full：可報告部門成員2021-01-012021-12-310001121404IFRS-Full：運營部門成員2022-01-012022-06-300001121404IFRS-Full：運營部門成員2021-01-012021-06-300001121404IFRS-Full：運營部門成員2021-01-012021-12-310001121404IFRS-FULL：材料對賬項目成員2022-01-012022-06-300001121404IFRS-FULL：材料對賬項目成員2021-01-012021-06-300001121404IFRS-FULL：材料對賬項目成員2021-01-012021-12-310001121404SNY：製藥公司成員2022-06-300001121404SNY：疫苗成員2022-06-300001121404SNY：Consumer Healthcare細分市場成員2022-06-300001121404IFRS-Full：可報告部門成員2022-06-300001121404SNY：製藥公司成員2021-06-300001121404SNY：疫苗成員2021-06-300001121404SNY：Consumer Healthcare細分市場成員2021-06-300001121404IFRS-Full：可報告部門成員2021-06-300001121404SNY：製藥公司成員2021-01-012021-06-300001121404SNY：疫苗成員2021-01-012021-06-300001121404SNY：製藥公司成員2021-12-310001121404SNY：疫苗成員2021-12-310001121404SNY：Consumer Healthcare細分市場成員2021-12-310001121404IFRS-Full：可報告部門成員2021-12-310001121404SNY：可報告的地理區域成員2022-01-012022-06-300001121404國家：法國2022-01-012022-06-300001121404SRT：北美成員2022-01-012022-06-300001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2022-01-012022-06-300001121404SNY：可報告的地理區域成員2022-06-300001121404SRT：歐洲成員2022-06-300001121404國家：法國2022-06-300001121404SRT：北美成員2022-06-300001121404國家：美國2022-06-300001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2022-06-300001121404SNY：可報告的地理區域成員2021-01-012021-06-300001121404國家：法國2021-01-012021-06-300001121404SRT：北美成員2021-01-012021-06-300001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-01-012021-06-300001121404SNY：可報告的地理區域成員2021-06-300001121404SRT：歐洲成員2021-06-300001121404國家：法國2021-06-300001121404SRT：北美成員2021-06-300001121404國家：美國2021-06-300001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-06-300001121404SNY：可報告的地理區域成員2021-01-012021-12-310001121404SRT：歐洲成員2021-01-012021-12-310001121404國家：法國2021-01-012021-12-310001121404SRT：北美成員2021-01-012021-12-310001121404國家：美國2021-01-012021-12-310001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-01-012021-12-310001121404SNY：可報告的地理區域成員2021-12-310001121404SRT：歐洲成員2021-12-310001121404國家：法國2021-12-310001121404SRT：北美成員2021-12-310001121404國家：美國2021-12-310001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-12-310001121404SNY：CertainWholesAlersInTheUnitedStates成員2022-01-012022-06-300001121404SNY：客户一號成員2022-01-012022-06-300001121404SNY：客户兩個成員2022-01-012022-06-300001121404SNY：客户三人2022-01-012022-06-300001121404SNY：客户一號成員2021-01-012021-06-300001121404SNY：客户兩個成員2021-01-012021-06-300001121404SNY：客户三人2021-01-012021-06-30 美國
美國證券交易委員會
華盛頓特區，20549
表格6-K
外國私人發行人報告
根據規則第13a-16或15d-16
根據1934年的《證券交易法》
2022年7月
委託公文編號：001-31368
賽諾菲
(註冊人姓名英文譯本)
法國巴黎75008號，法國博埃蒂街54號
(主要執行辦公室地址)
用複選標記表示註冊人是否在封面表格20-F或表格40-F下提交或將提交年度報告。
Form 20-F ☒ Form 40-F ☐
用複選標記表示註冊人是否按照S-T規則第101(B)(1)條所允許的紙質形式提交表格6-K：☐
用複選標記表示註冊人是否按照S-T規則第101(B)(7)條所允許的紙質形式提交表格6-K：☐
通過勾選標記表示註冊人是否也根據1934年《證券交易法》第12g3-2(B)條向委員會提供了本表格中所包含的信息。
Yes ☐ No ☒
如“是”，請在下方註明根據第12g3-2(B)條分配給註冊人的檔案編號：82-
2022年7月，賽諾菲發佈了作為附件99.1和99.2的財務報表和半年管理報告，在此引用作為參考。
2022年半年財務報告
目錄表
| | | | | | | | | | | |
| 1. | 簡明半年合併財務報表 | 2 |
| 合併資產負債表--資產 | 2 |
| 綜合資產負債表--股東權益和負債 | 3 |
| 合併損益表 | 4 |
| 綜合全面收益表 | 5 |
| 合併權益變動表 | 6 |
| 合併現金流量表 | 9 |
| 截至2022年6月30日的簡明半年合併財務報表附註 | 11 |
| | 引言 | 11 |
| | A/編制半年財務報表和會計政策的依據 | 11 |
| | B/2022年上半年的重要信息 | 15 |
| | C/2022年6月30日之後的事件 | 39 |
| 2 | 半年管理報告 | 40 |
| | A/2022年上半年的重大事件 | 40 |
| | B/實施企業社會責任戰略的進展情況 | 44 |
| | C/2022年6月30日之後的事件 | 48 |
| | D/2022年上半年合併財務報表 | 49 |
| | E/風險因素和關聯方交易 | 66 |
| | F/Outlook | 67 |
| | G/附錄-研究和開發管道 | 69 |
| 3 | 法定核數師報告 | 72 |
| 4 | 核證員責任書--半年財務報告 | 73 |
展品清單
| | | | | | | | |
| 證物編號： | | 描述 |
| | |
| 附件99.1 | 2022年簡明半年合併財務報表 | |
| 展品99.2 | 2022年半年管理報告、法定審計師報告和責任説明 | |
展品索引
| | | | | | | | |
| 證物編號： | | 描述 |
| | |
| 附件99.1 | 2022年簡明半年合併財務報表 | |
| 展品99.2 | 2022年半年管理報告、法定審計師報告和責任説明 | |
簽名
根據1934年《證券交易法》的要求，註冊人已正式促使本報告由正式授權的簽署人代表其簽署。
| | | | | | | | | | | | | | | | | | | | |
| | | | | | |
日期：2022年7月28日 | | | | | | 賽諾菲 |
| | | | | | |
| | | | 發信人： | | /s/亞歷山德拉·羅傑 |
| | | | 姓名： | | 亞歷山德拉·羅傑 |
| | | | 標題： | | 證券法和資本市場部主管 |